TY - JOUR
T1 - Photoimmunoconjugates
T2 - novel synthetic strategies to target and treat cancer by photodynamic therapy
AU - Fernandes, Sara R.G.
AU - Fernandes, Rosa
AU - Sarmento, Bruno
AU - Pereira, Patrícia M.R.
AU - Tomé, João P.C.
N1 - Funding Information:
The authors thank Fundação para a Ciência e a Tecnologia (FCT) for the financial support to CQE (FCT UID/QUI/0100/ 2013), CNC.IBILI (FCT UID/NEU/04539/2013 and POCI-01-0145-FEDER-007440) and i3S (POCI-01-0145-FEDER-007274 and NORTE-01-0145-FEDER-000012) research units, through national funds and where applicable co-financed by FEDER, within the PT2020 Partnership Agreement. We thank Professor Jason Lewis, Department of Radiology Memorial Sloan Kettering New York - USA, for reading the manuscript and insightful comments. Sara Fernandes acknowledges FCT for her Ph. D. scholarship SFRH/BD/129200/2017 and PMRP acknowledges the Tow Foundation Postdoctoral Fellowship from the MSKCC Center for Molecular Imaging and Nanotechnology.
Publisher Copyright:
© The Royal Society of Chemistry.
PY - 2019
Y1 - 2019
N2 - Photodynamic therapy (PDT) combines a photosensitizer (PS) with the physical energy of non-ionizing light to trigger cell death pathways. PDT has potential as a therapeutic modality to be used in alternative or in combination with other conventional cancer treatment protocols (e.g. surgery, chemotherapy and radiotherapy). Still, due to the lack of specificity of the current PSs to target the tumor cells, several studies have exploited their conjugation with targeting moieties. PSs conjugated with antibodies (Abs) or their fragments, able to bind antigens overexpressed in the tumors, have demonstrated potential in PDT of tumors. This review provides an overview of the most recent advances on photoimmunoconjugates (PICs) for cancer PDT, which involve the first and second-generation PSs conjugated to Abs. This is an update of our previous review “Antibodies armed with photosensitizers: from chemical synthesis to photobiological applications”, published in 2015 in Org. Biomol. Chem.
AB - Photodynamic therapy (PDT) combines a photosensitizer (PS) with the physical energy of non-ionizing light to trigger cell death pathways. PDT has potential as a therapeutic modality to be used in alternative or in combination with other conventional cancer treatment protocols (e.g. surgery, chemotherapy and radiotherapy). Still, due to the lack of specificity of the current PSs to target the tumor cells, several studies have exploited their conjugation with targeting moieties. PSs conjugated with antibodies (Abs) or their fragments, able to bind antigens overexpressed in the tumors, have demonstrated potential in PDT of tumors. This review provides an overview of the most recent advances on photoimmunoconjugates (PICs) for cancer PDT, which involve the first and second-generation PSs conjugated to Abs. This is an update of our previous review “Antibodies armed with photosensitizers: from chemical synthesis to photobiological applications”, published in 2015 in Org. Biomol. Chem.
UR - http://www.scopus.com/inward/record.url?scp=85062447206&partnerID=8YFLogxK
U2 - 10.1039/C8OB02902D
DO - 10.1039/C8OB02902D
M3 - Review article
C2 - 30648722
AN - SCOPUS:85062447206
SN - 1477-0520
VL - 17
SP - 2579
EP - 2593
JO - Organic and Biomolecular Chemistry
JF - Organic and Biomolecular Chemistry
IS - 10
ER -